Circulating Biomarkers for Predicting Disease Progression in Idiopathic Pulmonary Fibrosis: Insights into Precision Medicine.

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease with increasing incidence and poor prognosis, with a median survival of approximately 3 years. Although antifibrotic therapies such as nintedanib and pirfenidone offer modest benefits in slowing disease progression. In addition, nerandomilast, a selective phosphodiesterase-4B inhibitor recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of IPF and progressive pulmonary fibrosis (PPF), has demonstrated efficacy in slowing disease progression. Acute exacerbations significantly contribute to mortality, with a median survival of approximately 4 months. Current demographic, clinical, physiological, and radiological parameters provide limited prognostic insights, often detecting disease only after substantial pulmonary damage has occurred. This underscores an urgent need for circulating biomarkers capable of detecting early disease progression, including subtle declines in lung function and radiologic progression of fibrosis, before clinically apparent deterioration occurs. Such biomarkers may allow earlier identification of patients at risk of rapid disease progression by detecting biological changes that precede measurable declines in forced vital capacity or radiologic progression on high-resolution computed tomography. Among emerging approaches for disease monitoring and prognostic assessment, blood-based biomarkers have emerged as promising tools for assessing disease progression and prognosis due to their minimally invasive nature. However, the reproducibility and validation of these biomarkers across diverse populations remain suboptimal. Integrating multiple biomarkers with established clinical and radiological parameters holds the potential to enhance prognostic precision. While high-resolution computed tomography (HRCT) is pivotal for diagnosis, its prognostic utility remains constrained. This review delves into the latest advancements in biomarker research for IPF, shedding light on their prospective applications in disease monitoring, therapeutic stratification, and the paradigm of precision medicine. PURPOSE: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease with increasing incidence and poor prognosis, with a median survival of approximately 3 years. Although antifibrotic therapies such as nintedanib and pirfenidone offer modest benefits in slowing disease progression, nerandomilast, a selective phosphodiesterase-4B inhibitor recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of IPF and progressive pulmonary fibrosis (PPF), has demonstrated efficacy in slowing disease progression. Acute exacerbations significantly contribute to mortality, with a median survival of approximately 4 months. This review aims to summarize current evidence on circulating biomarkers for predicting disease progression in IPF.

methodsA comprehensive review of the literature was conducted to identify studies evaluating circulating biomarkers associated with disease progression and prognosis in IPF, with a focus on clinically relevant biomarkers and their relationship with physiological and radiological parameters.

resultsCurrent demographic, clinical, physiological, and radiological parameters provide limited prognostic insights, often detecting disease only after substantial pulmonary damage has occurred. Circulating biomarkers have emerged as promising tools for detecting early disease progression, including subtle declines in lung function and radiologic progression of fibrosis before clinically apparent deterioration occurs. These biomarkers may enable earlier identification of patients at risk of rapid disease progression by capturing biological changes that precede measurable declines in forced vital capacity or progression on high-resolution computed tomography (HRCT). However, their reproducibility and validation across diverse populations remain suboptimal. Integrating multiple biomarkers with established clinical and radiological parameters may enhance prognostic precision.

conclusionWhile HRCT remains pivotal for diagnosis, its prognostic utility is limited. Circulating biomarkers hold significant potential for improving disease monitoring, therapeutic stratification, and advancing precision medicine in IPF, although further validation is required before routine clinical implementation.